Drugs / P11187
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01874366 | Jun 2013 → Oct 2015 | obesity disorder, type 2 diabetes mellitus | Piramal Enterprises Limited | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | P11187 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01874366 ↗ |
| Action | Activate | “Oral G-Protein Coupled Receptor 40(GPR40)agonist” NCT01874366 ↗ |
| Route | Oral | “Step wise dose escalation(10 to 1500 mg, qd, Oral)” NCT01874366 ↗ |